Get started
Author

Angela Listì

Observed names: A. Listi, A. Listì, Angela Listi, Angela Listi', Angela Listì, LISTI', Angela, Listi, Angela, Listì, A, Listì, Angela
Observed institutions: Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo, Institut Paoli-Calmettes, Ospedale San Luigi Gonzaga, University of Turin, University of Palermo
ORCID: 0000-0002-0617-6184
Observed ORCID: 0000-0002-0617-6184
OpenAlex ID: A5084174977
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
2018 · Giuseppe Badalamenti, Daniele Fanale, et al. · Cellular Immunology · 248
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway
2017 · Laura La Paglia, Angela Listì, et al. · PPAR Research · 174
PDF
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
2016 · Francesco Passiglia, Giuseppe Bronte, et al. · Oncotarget · 165
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
2016 · Daniela Massihnia, Antonio Galvano, et al. · Oncotarget · 141
PDF
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
2019 · Lorena Incorvaia, Daniele Fanale, et al. · Advances in Therapy · 125
PDF
Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?
2015 · Daniele Fanale, Giuseppe Bronte, et al. · Analytical Cellular Pathology · 112
PDF
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
2018 · Francesco Passiglia, Sergio Rizzo, et al. · Scientific Reports · 93
PDF
Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab
2017 · Francesco Passiglia, Antonio Galvano, et al. · International Journal of Cancer · 91
PDF
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
2019 · Francesco Passiglia, Antonio Galvano, et al. · Therapeutic Advances in Medical Oncology · 65
PDF
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
2021 · Umberto Malapelle, Francesco Passiglia, et al. · European Journal of Cancer · 43
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus
2016 · Daniela Cabibi, Stefano Caruso, et al. · Oncotarget · 41
PDF
Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis
2018 · Francesco Passiglia, Sergio Rizzo, et al. · Current Cancer Drug Targets · 40
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
2016 · Giuseppe Bronte, Lorena Incorvaia, et al. · Critical Reviews in Oncology/Hematology · 38
Nintedanib in non-small cell lung cancer: from preclinical to approval
2015 · Christian Caglevic, Massimiliano Grassi, et al. · Therapeutic Advances in Respiratory Disease · 32
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design
2020 · Francesco Passiglia, Paolo Bironzo, et al. · Clinical Lung Cancer · 30
PDF
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer
2016 · Francesco Passiglia, Rafael Caparica, et al. · Expert Opinion on Investigational Drugs · 30
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
2015 · Francesco Passiglia, Giuseppe Bronte, et al. · Expert Opinion on Biological Therapy · 27
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
2023 · Francesco Passiglia, Luisella Righi, et al. · Clinical Cancer Research · 26
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer
2021 · Caterina De Luca, Francesco Pepe, et al. · Cancers · 26
PDF
“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
2016 · Lorena Incorvaia, Francesc Passiglia, et al. · Oncotarget · 26
PDF
Non-coding RNAs Functioning in Colorectal Cancer Stem Cells
2016 · Daniele Fanale, Nadia Barraco, et al. · Advances in experimental medicine and biology · 26
Nintedanib in NSCLC: evidence to date and place in therapy
2016 · Giuseppe Bronte, Francesco Passiglia, et al. · Therapeutic Advances in Medical Oncology · 24
PDF
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality
2023 · Giovanni Farinea, Veronica Crespi, et al. · Journal of Thoracic Oncology · 23
PDF
Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
2021 · Francesca Napoli, Angela Listì, et al. · Cancers · 22
PDF
EGFR inhibition in NSCLC: New findings…. and opened questions?
2017 · Francesco Passiglia, Angela Listì, et al. · Critical Reviews in Oncology/Hematology · 22
Works count: 107
Citation count: 1,951
H-index: 23
I10-index: 37
Year
Topic
Type